// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Performance of potential definitions of remission in systemic lupus erythematosus (SLE versus quality of life over 5 years in swedish patients with recent-onset sle

M. Björk - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Performance of referral strategies for spondyloarthritis: a population-based nationwide study

A. Sepriano - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost effective strategy in spondyloarthritis

S. Dubash - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

Infliximab

Phenotype of anca associated vasculitis associates with major cardiovascular events: a retrospective observational study from the leeds vasculitis cohort

A. Giollo - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ischemic stroke

N/A

Physical activity awareness and preferences in rheumatic diseases: a qualitative study.

P. Vitalis - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Physician-reported behaviours and treatment trends of tumour necrosis factor inhibitor use: cycling versus switching in five european countries: france, germany, italy, spain and the uk

J.R. Curtis - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predicting work disability, pension claim, absenteeism and presenteeism in ra patients

A.D. Houssien - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Prediction of persistent knee pain by pressure pain detection thresholds: results from the knee pain in the community cohort (KPIC

D.F. Mcwilliams - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictors and temporal trend of seasonal influenza vaccination in auto-immune rheumatic diseases in the uk: a nationwide prospective cohort study

G. Nakafero - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Influenza

N/A

Predictors for disease worsening defined by organ failure in diffuse systemic sclerosis: a european scleroderma trials and research (EUSTAR analysis

M.O. Becker - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Pregnancy outcomes and disease activity in women with axial spondyloarthritis: a systematic literature review

A. Moltó - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Pregnancy outcomes in mixed connective tissue disease: results from a multicentre cohort study

M. Radin - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Pregnancy outcomes in patients with iga vasculitis

J Nossent - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Henoch-Schonlein purpura nephritis

N/A

Pregnancy outcomes in women with antiphospholipid antibodies: interim results from a single centre cohort study

K. Schreiber - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Prevalence of type 2 diabetes and evaluation of patient characteristics among patients with and without ra from community rheumatologyclinics

E. Alemao - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Prevention of rmds – what have we learned?

S.M. Verstappen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prognostic markers in axial spondyloarthritis (PROMISE – cross sectional evaluation of serum biomarkers in axspa, mechanical back pain and healthy controls

E. Reilly - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Progressive fibrosing interstitial lung disease (PF-ILD in patients with autoimmune rheumatic diseases

A. Fischer - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Progressive skin fibrosis is associated with a decline in lung function and poorer survival in patients with diffuse cutaneous systemic sclerosis: a european scleroderma trials and research (EUSTAR analysis

W. Wu - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

N/A

Prolonged proton pump inhibitor exposure is associated with development of calcinosis in systemic sclerosis

L.V. Host - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Copyright © 2026. QuantiNova All rights reserved